Published in Gene Therapy Weekly, December 13th, 2001
Replagal (agalsidase alfa) enzyme replacement therapy for Fabry disease received marketing approval in the European Union in August 2001. With the establishment of reimbursement in three countries, the product was launched in late September. During the third quarter of 2001, TKT also continued to record product sales under a compassionate use program, resulting in total sales of $537,000. License and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.